In the US and North America, Marksans Pharma’s formulation business reported revenues of ₹387.3 crore in Q2 FY26, demonstrating robust performance despite macroeconomic headwinds. Tariff uncertainties have now stabilised, supporting steady operations. Shares of Marksans Pharma Ltd ended at ₹187.00, down by ₹9.60, or 4.88%, on the BSE.
